Cardiomyocyte PRL2 Promotes Cardiac Hypertrophy via Directly Dephosphorylating AMPKα2
Xue Han(Hangzhou Medical College), Bozhi Ye(Wenzhou Medical University), Qiaojuan Shi(Hangzhou Medical College), Y Liu(Hangzhou Medical College), Shiju Ye(Wenzhou Medical University), Huazhong Ying(Hangzhou Medical College), Jiajia Zhang(Bloomberg (United States)), Yanmei Zhang(Inner Mongolia People's Hospital), Junqing Wang(Zhejiang Provincial People's Hospital), Jiajia Wei(Zunyi Medical University), Ruyi Zheng(Hangzhou Medical College), Yu Tu(Hangzhou Medical College), Mengyang Wang(Beihua University), Weiqi Li
Cited by 13
Related Papers
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
|Nature|2021|546
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer
|JAMA Oncology|2020|498
PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics
|Molecular Medicine Reports|2017|237
<p>Emodin alleviates myocardial ischemia/reperfusion injury by inhibiting gasdermin D-mediated pyroptosis in cardiomyocytes</p>
|Drug Design Development and Therapy|2019|187